United States — Food and Drug Administration & Bronstein, Gewirtz & Grossman, LLC
8 shared events · Importance 4 · Last updated Aug 21, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration issued safety warnings concerning serious neurological complications in dogs related to Zoetis' Bedinvetmab, contributing to its weakening adoption.
Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman, LLC is a law firm that has filed a class action lawsuit against Zoetis, representing investors who suffered losses due to alleged securities fraud.
May 18, 2026 · 316 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.
Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman, LLC is an investor-rights law firm that has filed a class action lawsuit against Aldeyra Therapeutics, seeking to recover damages for investors.
Apr 24, 2026 · 80 articles
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.
Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ImmunityBio and its officers, alleging violations of federal securities laws.
Apr 02, 2026 · 132 articles
Regulatory
United States — Food and Drug Administration: The FDA placed a full clinical hold on ARD-101's IND, halting all ongoing studies. This regulatory action is central to the lawsuit and has severely impacted Aardvark's operations and stock price.
Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman, LLC is one of the law firms that announced the class action and is seeking lead plaintiffs. The firm represents investors on a contingency basis and stands to gain from a successful recovery.
Aug 14, 2026 · 23 articles
Regulatory
United States — Food and Drug Administration: The FDA rejected Replimune's BLA and published briefing documents raising concerns about the data package, triggering the stock drop and subsequent lawsuits. The FDA's actions are central to the event.
Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman, LLC filed a class action lawsuit against Replimune, seeking damages for investors. The firm is actively recruiting lead plaintiffs.
Jul 29, 2026 · 65 articles
Regulatory
United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.
Bronstein, Gewirtz & Grossman, LLC: Filed a class action lawsuit against Capricor.
Jul 27, 2026 · 293 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Bronstein, Gewirtz & Grossman, LLC interact across events, view sentiment trends, and discover connected entities.
Open Dashboard